Nuo TherapeuticsAURX 33 Pretax Margin % is -47.47% as of Mar. 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Nuo Therapeutics ranks better than 54.45% on this metric.
The historical rank and industry rank for Nuo Therapeutics's Pretax Margin % or its related term are showing as below:
AURX'
s Pretax Margin % Range Over the Past 10 Years
Min: -2832.14 Med: -520.69 Max: -57.71
Current: -57.71
AURX's Pretax Margin % is ranked better than 54.45% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs AURX: -57.71
Nuo Therapeutics (OTCPK:AURX) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nuo Therapeutics Pretax Margin % Related Terms
Nuo Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AURX vs PDSB, LTRN, VERU: Pretax Margin % Comparison
For the Biotechnology subindustry, Nuo Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuo Therapeutics (AURX) has a Pretax Margin % of -47.47% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nuo Therapeutics and its competitors. According to the industry distribution chart, Nuo Therapeutics ranks #430 out of 944 companies in the Biotechnology industry, placing it in the top 45.6%.
Is Nuo Therapeutics' Pretax Margin % too high?
Nuo Therapeutics' current Pretax Margin % is -47.47%. Based on the distribution chart, Nuo Therapeutics ranks #430 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Pretax Margin % compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #430 out of 944 companies for Pretax Margin %. This puts Nuo Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current Pretax Margin % is -47.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current Pretax Margin % is -47.47%. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Pretax Margin % is -47.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
Pretax Margin %: -47.47%
GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
